Sugimoto, Yoshikazu

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 化学療法学講座 (Shiba-Kyoritsu)

Position

Professor

Related Websites

External Links

Academic Background 【 Display / hide

  • 1980.03

    The University of Tokyo, Faculty of Pharmaceutical Science, 薬学科

    University, Graduated

  • 1985.03

    The University of Tokyo, Graduate School of Pharmaceutical Sciences, 生命薬学専攻

    Graduate School, Completed, Doctoral course

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy (Clinical Pharmaceutical Science)

Research Keywords 【 Display / hide

  • ABC transporter

  • molecular targer therapy

  • anticancer drug resistance

  • gene therapy

 

Books 【 Display / hide

  • がん化学療法・分子標的治療update.

    杉本芳一., 中外医学社, 東京, 2009.10

    Scope: 59-63

  • がん薬物療法学.

    杉本芳一., 大阪/日本臨床社, 2009.01

    Scope: 349-355

  • がんの分子標的治療.

    '野口耕司, 杉本芳一.', 東京/南山堂, 2008.09

    Scope: 278-290

  • 薬剤師生涯研修ガイド.

    杉本芳一., 東京/学校法人医学アカデミー出版部, 2008.05

    Scope: 223-224

  • 薬学の未来を拓く.

    杉本芳一., 東京/慶應義塾, 2008.04

    Scope: 72-81

display all >>

Papers 【 Display / hide

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

    Noguchi K, Katayama K, Sugimoto Y*.

    Pharmacogenomics and Personalized Medicine (Dove medical Press)  7   53-64 2014.02

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • トランスポーターの遺伝子多型.

    杉本芳一.

    がん分子標的治療 (メディカルレビュー社)  9(3)   29-35 2011.07

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • 分子標的薬.

    杉本芳一.

    薬局 (南山堂)  61(2)   11 2010.02

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • 抗悪性腫瘍薬の薬理学・薬力学・薬理遺伝学ー薬物相互作用.

    杉本芳一.

    日本臨床 (日本臨床社)  67, Suppl 1   349-355 2009.01

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • 抗癌剤開発における民族差について.

    杉本芳一.

    臨床評価 (/臨床評価刊行会)  33(2)   393-398 2006.04

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

display all >>

Presentations 【 Display / hide

  • カチオニック修飾はdextranにBCRP阻害効果を付与する

    森本かおり, 石井敬, 杉本芳一, 荻原琢男, 富田幹雄.

    日本薬物動態学会第36回年会, 

    2021.11

    Poster presentation

  • WEE1阻害薬耐性細胞におけるAKTの活性化

    奥田賢, 近藤慎吾, 加藤優, 杉本芳一.

    第65回日本薬学会関東支部大会, 

    2021.09

    Oral presentation (general)

  • Side population細胞に対するepigenetic阻害薬の効果

    春名俊志, 加藤優, 近藤慎吾, 杉本芳一.

    第65回日本薬学会関東支部大会, 

    2021.09

    Oral presentation (general)

  • エピジェネティック阻害剤によるSP細胞形質の抑制

    加藤優, 近藤慎吾, 杉本芳一.

    第25回日本がん分子標的治療学会学術集会, 

    2021.05

    Oral presentation (general)

  • FLT3-ITDによるintegrated stress response の誘導

    佐々木大河, 加藤優, 片山和浩, 近藤慎吾, 杉本芳一

    日本薬学会第141回年会, 

    2021.03

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 複数のがん分子標的治療薬の効果を左右する薬剤耐性・感受性規定因子の統合的研究

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • Analysis of the resistance mechanisms to molecular-targeting anticancer agents

    2018.04
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • Identification of factors regulating the capacity for both self-renewal and pluripotent differentiation of cancer stem cells and application to cancer treatment.

    2015.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Exploratory Research, Principal investigator

     View Summary

    SP(+) cells have a property of Hoechst 33342 exclusion and are considered as stem-like cells. SP(+) cells isolated from human colorectal cancer 116/slug-25 cells showed higher expression of drug efflux transporter ABCG2 and histone acetyl transferase HAT1, and lower expression of histone methyltransferase EZH2 than SP(-) cells. Treatment of 116/slug-25 cells with inhibitors of histone acetyltransferases and methyltransferases diminished SP(+) cells. Genes regulating this SP(+) phenotype have been identified from a screening with shRNA library.

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (CHEMOTHERAPY)

    2022

  • SEMINAR: (CHEMOTHERAPY)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2022

  • PHARMACEUTICAL SCIENCES OF DISEASES

    2022

display all >>